Key result
QSAR models based on simplex representation successfully predicted CC50, IC50, and SI values for [(biphenyloxy)propyl]isoxazole derivatives against human rhinovirus 2 (R2 = 0.838 - 0.918).
Population
HeLa cells and human rhinovirus 2 (HRV-2)
Design
Preclinical
Authors
Loading...
May accelerate preclinical antiviral screening; leaves open clinical translation pending human trials.
QSAR models successfully predicted the antiviral activity of [(biphenyloxy)propyl]isoxazole derivatives against human rhinovirus 2, leading to the design of three new active compounds.
Kuz’min et al. (2007) studied Human rhinovirus 2 (HRV-2) infection. [(biphenyloxy)propyl]isoxazole derivatives was evaluated on 50% cytotoxic concentration (CC50), 50% inhibitory concentration (IC50), and selectivity index (SI). QSAR models based on simplex representation successfully predicted CC50, IC50, and SI values for [(biphenyloxy)propyl]isoxazole derivatives against human rhinovirus 2 (R2 = 0.838 - 0.918).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: